menu
    • menu
    [{"orgOrder":0,"company":"Eden Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"JHL1101","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eden Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Microbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MS-20","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Microbio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Microbio \/ Undisclosed"},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Mycenax Biotech","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Mycenax Biotech \/ Gedeon Richter","highestDevelopmentStatusID":"6","companyTruncated":"Mycenax Biotech \/ Gedeon Richter"},{"orgOrder":0,"company":"HoHo Biotech","sponsor":"Tri-Service General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Hydrogen","moa":"None","graph1":"Immunology","graph2":"Phase I","graph3":"HoHo Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HoHo Biotech \/ Tri-Service General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"HoHo Biotech \/ Tri-Service General Hospital"},{"orgOrder":0,"company":"HoHo Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Hydrogen","moa":"None","graph1":"Immunology","graph2":"Phase I","graph3":"HoHo Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HoHo Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HoHo Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Regimmune","sponsor":"Zachariah Michael DeFilipp","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Immunology","graph2":"Phase I","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regimmune \/ Zachariah Michael DeFilipp","highestDevelopmentStatusID":"6","companyTruncated":"Regimmune \/ Zachariah Michael DeFilipp"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Microbio

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Microbio

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MS-20,Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Microbio's "MS-20" Shows Promise as Add-On Therapy for Ulcerative Colitis

                            Details : MS-20 is a postbiotic produced through the symbiotic fermentation of multi-strain probiotics. It is being investigated for immunological and gastrointestinal diseases.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : MS-20,Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HoHo Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HoHo Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrogen

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Safety of Treating Rheumatologic and Metabolic Patients With Molecular Hydrogen Supplement.

                            Details : Hydrogen is a Dietary Supplement drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Autoimmune Diseases.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            January 19, 2022

                            Lead Product(s) : Hydrogen

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HoHo Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HoHo Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrogen

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Tri-Service General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Safety of Treating Autoimmune Diseases With Molecular Hydrogen Supplement

                            Details : Hydrogen is a Dietary Supplement drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Autoimmune Diseases.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            November 10, 2021

                            Lead Product(s) : Hydrogen

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Tri-Service General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Regimmune

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Regimmune

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fludarabine Phosphate

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Zachariah Michael DeFilipp

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Haplo Peripheral Blood Sct In GVHD Prevention

                            Details : Fludarabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Graft vs Host Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 16, 2020

                            Lead Product(s) : Fludarabine Phosphate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Zachariah Michael DeFilipp

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mycenax Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Mycenax Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tocilizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Gedeon Richter

                            Deal Size : $19.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Richter and Mycenax Entered into an Asset Purchase Agreement of Biosimilar Tocilizumab

                            Details : Richter receives worldwide rights to develop, manufacture and commercialise the biosimilar tocilizumab for the treatment of rheumatoid arthritis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $3.0 million

                            April 29, 2020

                            Lead Product(s) : Tocilizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Gedeon Richter

                            Deal Size : $19.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TaiwanJ Pharmaceuticals

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TaiwanJ Pharmaceuticals

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JKB-122

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule

                            Details : JKB-122 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis, Autoimmune.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2020

                            Lead Product(s) : JKB-122

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            United BioPharma

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United BioPharma

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-221

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontane...

                            Details : UB-221 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chronic Urticaria.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 25, 2019

                            Lead Product(s) : UB-221

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            United BioPharma

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United BioPharma

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-221

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CS...

                            Details : UB-221 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chronic Urticaria.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 15, 2018

                            Lead Product(s) : UB-221

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eden Biologics

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Eden Biologics

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JHL1101

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis

                            Details : JHL1101 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 19, 2017

                            Lead Product(s) : JHL1101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth